morinlab.bib
... ...
@@ -1,3 +1,45 @@
1
+@article{camusXPO1CellHematological2017,
2
+ title = {{{XPO1}} in {{B}} Cell Hematological Malignancies: From Recurrent Somatic Mutations to Targeted Therapy},
3
+ shorttitle = {{{XPO1}} in {{B}} Cell Hematological Malignancies},
4
+ author = {Camus, Vincent and Miloudi, Hadjer and Taly, Antoine and Sola, Brigitte and Jardin, Fabrice},
5
+ year = 2017,
6
+ month = feb,
7
+ journal = {Journal of Hematology \& Oncology},
8
+ volume = {10},
9
+ number = {1},
10
+ pages = {47},
11
+ issn = {1756-8722},
12
+ doi = {10.1186/s13045-017-0412-4},
13
+ urldate = {2026-01-21},
14
+ abstract = {Many recent publications highlight the large role of the pivotal eukaryotic nuclear export protein exportin-1 (XPO1) in the oncogenesis of several malignancies, and there is emerging evidence that XPO1 inhibition is a key target against cancer. The clinical validation of the pharmacological inhibition of XPO1 was recently achieved with the development of the selective inhibitor of nuclear export compounds, displaying an interesting anti-tumor activity in patients with massive pre-treated hematological malignancies. Recent reports have shown molecular alterations in the gene encoding XPO1 and showed a mutation hotspot (E571K) in the following two hematological malignancies with similar phenotypes and natural histories: primary mediastinal diffuse large B cell lymphoma and classical Hodgkin's lymphoma. Emerging evidence suggests that the mutant XPO1 E571K plays a role in carcinogenesis, and this variant is quantifiable in tumor and plasma cell-free DNA of patients using highly sensitive molecular biology techniques, such as digital PCR and next-generation sequencing. Therefore, it was proposed that the XPO1 E571K variant may serve as a minimal residual disease tool in this setting. To clarify and summarize the recent findings on the role of XPO1 in B cell hematological malignancies, we conducted a literature search to present the major publications establishing the landscape of XPO1 molecular alterations, their impact on the XPO1 protein, their interest as biomarkers, and investigations into the development of new XPO1-targeted therapies in B cell hematological malignancies.},
15
+ langid = {english},
16
+ keywords = {Exportin,Lymphoma,Minimal residual disease,Targeted therapy,XPO1},
17
+ file = {/Users/rmorin/Zotero/storage/RM8HLVIZ/Camus et al. - 2017 - XPO1 in B cell hematological malignancies from recurrent somatic mutations to targeted therapy.pdf}
18
+}
19
+
20
+
21
+@article{balasubramanianSelectiveInhibitionNuclear2022,
22
+ title = {Selective Inhibition of Nuclear Export: A Promising Approach in the Shifting Treatment Paradigms for Hematological Neoplasms},
23
+ shorttitle = {Selective Inhibition of Nuclear Export},
24
+ author = {Balasubramanian, Suresh Kumar and Azmi, Asfar S. and Maciejewski, Jaroslaw},
25
+ year = 2022,
26
+ month = mar,
27
+ journal = {Leukemia},
28
+ volume = {36},
29
+ number = {3},
30
+ pages = {601--612},
31
+ publisher = {Nature Publishing Group},
32
+ issn = {1476-5551},
33
+ doi = {10.1038/s41375-021-01483-z},
34
+ urldate = {2026-01-21},
35
+ abstract = {Novel targeted therapeutics alone or in rational combinations are likely to dominate the future management of various hematological neoplasms. However, the challenges currently faced are the molecular heterogeneity in driver lesions and genetic plasticity leading to multiple resistance pathways. Thus, progress has overall been gradual. For example, despite the advent of targeted agents against actionable drivers like FLT3 in acute myeloid leukemia (AML), the prognosis remains suboptimal in newly diagnosed and dismal in the relapsed/refractory (R/R) setting, due to other molecular abnormalities contributing to inherent and acquired treatment resistance. Nuclear export inhibitors are of keen interest because they can inhibit several active tumorigenic processes simultaneously and also synergize with other targeted drugs and chemotherapy. XPO1 (or CRM1, chromosome maintenance region 1) is one of the most studied exportins involved in transporting critical cargoes, including tumor suppressor proteins like p27, p53, and RB1. Apart from the TSP cargo transport and its role in drug resistance, XPO1 inhibition results in retention of master transcription factors essential for cell differentiation, cell survival, and autophagy, rendering cells more susceptible to the effects of other antineoplastic agents, including targeted therapies. This review will dissect the role of XPO1 inhibition in hematological neoplasms, focusing on mechanistic insights gleaned mainly from work with SINE compounds. Future potential combinatorial strategies will be discussed.},
36
+ copyright = {2021 The Author(s)},
37
+ langid = {english},
38
+ keywords = {Drug development,Targeted therapies},
39
+ file = {/Users/rmorin/Zotero/storage/JS9P4ZZJ/Balasubramanian et al. - 2022 - Selective inhibition of nuclear export a promising approach in the shifting treatment paradigms for.pdf}
40
+}
41
+
42
+
1 43
@article{freemanMolecularDeterminantsOutcomes2022,
2 44
title = {Molecular Determinants of Outcomes in Relapsed or Refractory Mantle Cell Lymphoma Treated with Ibrutinib or Temsirolimus in the {{MCL3001}} ({{RAY}}) Trial},
3 45
author = {Freeman, Ciara L. and Pararajalingam, Prasath and Jin, Ling and Balasubramanian, Sriram and Jiang, Aixiang and Xu, Wendan and Grau, Michael and Zapukhlyak, Myroslav and Boyle, Merrill and Hodkinson, Brendan and Schaffer, Michael and Enny, Christopher and Deshpande, Sanjay and Sun, Steven and Vermeulen, Jessica and Morin, Ryan D. and Scott, David W. and Lenz, Georg},